Clinical Trials for Pediatric Neuroblastoma
4 Open Trials
| Trial Type | Protocol No. & Open Date | Summary |
|---|---|---|
| Therapeutic | COGANBL1221 03/28/2013 | ANBL1221 - A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC# 683864, IND# 61010) or Chimeric 14.18 Antibody (ch14.18) (NSC# 623408, IND# 4308) in Children with Refractory, Relapsed or Progressive Neuroblastoma |
| Therapeutic | VICCPED1249 08/06/2012 | An Open Label, Expanded Access Protocol using 131I-Metaiodobenzylguanidine (131I-MIBG) Therapy in Patients with Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma |
| Therapeutic | COGADVL0912 04/05/2011 | PH 1/2 Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-MET, in Children With Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma |
| Prevention | VICCPED12112 01/04/2013 | NMTRC003: A Phase II Preventative Trial of DFMO (eflornithine HCI) as a Single Agent in Patients with High Risk Neuroblastoma in Remission |
You do not have JavaScript enabled. This site works better with JavaScript turned on.
